Across TCGA pan-cancer cohorts, CXorf66 mass-spec protein differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of CXorf66’s most consistent transcriptional readouts.
The strongest signal is observed in lung adenocarcinoma (LUAD), where CXorf66 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types CXorf66 is over-expressed in tumor, although a few such as LUAD show the opposite, repressed pattern.
LUAD are the cancer types where CXorf66 tumor–normal differential expression is most reproducible.